Cargando…

Approved checkpoint inhibitors in bladder cancer: which drug should be used when?

The treatment of advanced metastatic urothelial carcinoma has recently evolved with the approval of five checkpoint inhibitors. In the second-line setting, in patients who have progressed on cisplatin-based chemotherapy, pembrolizumab, atezolizumab, durvalumab, nivolumab and avelumab are United Stat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ghatalia, Pooja, Zibelman, Matthew, Geynisman, Daniel M., Plimack, Elizabeth
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2018
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6066800/ https://www.ncbi.nlm.nih.gov/pubmed/30083254 http://dx.doi.org/10.1177/1758835918788310

Ejemplares similares

Comparative Effectiveness of Front-Line Ipilimumab and Nivolumab or Axitinib and Pembrolizumab in Metastatic Clear Cell Renal Cell Carcinoma
por: Zarrabi, Kevin K, et al.
Publicado: (2022)

Role of immunotherapy in localized muscle invasive urothelial cancer
por: Kaur, Jasmeet, et al.
Publicado: (2021)

The Evolution of Clinical Trials in Renal Cell Carcinoma: A Status Report for 2013–2016 from the ClinicalTrials.gov Website
por: Ghatalia, Pooja, et al.
Publicado: (2017)

A randomized phase 2 study of bicalutamide with or without metformin for biochemical recurrence in overweight or obese prostate cancer patients (BIMET-1)
por: Bilusic, Marijo, et al.
Publicado: (2022)

A Phase II Trial of Guadecitabine plus Atezolizumab in Metastatic Urothelial Carcinoma Progressing after Initial Immune Checkpoint Inhibitor Therapy
por: Jang, H. Josh, et al.
Publicado: (2023)

Role of perioperative immunotherapy in localized renal cell carcinoma
por: Kaur, Jasmeet, et al.
Publicado: (2023)

When and which patients should receive remdesivir?
por: Garcia-Vidal, Carolina, et al.
Publicado: (2022)

Clinical benefit of immune checkpoint inhibitors approved by US Food and Drug Administration
por: Liang, Fei, et al.
Publicado: (2020)

Advanced small cell carcinoma of the bladder: clinical characteristics, treatment patterns and outcomes in 960 patients and comparison with urothelial carcinoma
por: Geynisman, Daniel M., et al.
Publicado: (2015)

Cancer Immunotherapy Update: FDA-Approved Checkpoint Inhibitors and Companion Diagnostics
por: Twomey, Julianne D., et al.
Publicado: (2021)

Checkpoint Inhibitors for Advanced Bladder Cancer
por: Messing, Edward M.
Publicado: (2016)

Prescription Drugs Marketed in the United States Should Be Approved by the FDA
por: Shepherd, Marvin
Publicado: (2003)

Which ones, when and why should renin-angiotensin system inhibitors work against COVID-19?()
por: Montanari, Mariele, et al.
Publicado: (2021)

Current Status and Future Direction to Address Disparities in Diversity, Equity, and Inclusion in Prostate Cancer Care
por: Fu, Jerry, et al.
Publicado: (2023)

Immune Checkpoint Inhibitors for the Treatment of Bladder Cancer
por: Lopez-Beltran, Antonio, et al.
Publicado: (2021)

Advances and Controversies With Checkpoint Inhibitors in Bladder Cancer
por: Rhea, Logan P, et al.
Publicado: (2021)

Checkpoint and PARP inhibitors, for whom and when
por: Lee, Jung-Min, et al.
Publicado: (2017)

Molecular and Clinical Insights into the Role and Significance of Mutated DNA Repair Genes in Bladder Cancer
por: Abbosh, Philip H., et al.
Publicado: (2018)

Evolution of preclinical characterization and insights into clinical pharmacology of checkpoint inhibitors approved for cancer immunotherapy
por: Kasichayanula, Sreeneeranj, et al.
Publicado: (2022)

Patterns of toxicity burden for FDA-approved immune checkpoint inhibitors in the United States
por: Yang, Fan, et al.
Publicado: (2023)

Immune Checkpoint Inhibition in Advanced Non-Clear Cell Renal Cell Carcinoma: Leveraging Success from Clear Cell Histology into New Opportunities
por: Zarrabi, Kevin, et al.
Publicado: (2021)

Dual Checkpoint Inhibition with Ipilimumab plus Nivolumab After Progression on Sequential PD‐1/PDL‐1 Inhibitors Pembrolizumab and Atezolizumab in a Patient with Lynch Syndrome, Metastatic Colon, and Localized Urothelial Cancer
por: Winer, Arthur, et al.
Publicado: (2019)

Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021
por: Wu, Qing, et al.
Publicado: (2022)

Predicting response to checkpoint inhibitors in melanoma beyond PD-L1 and mutational burden
por: Morrison, Carl, et al.
Publicado: (2018)

FDA-Approved and Emerging Next Generation Predictive Biomarkers for Immune Checkpoint Inhibitors in Cancer Patients
por: Wang, Ye, et al.
Publicado: (2021)

What can the National Cancer Database tell us about disparities in advanced bladder cancer outcomes?
por: Joshi, Shreyas S., et al.
Publicado: (2018)

A Comprehensive Review of US FDA-Approved Immune Checkpoint Inhibitors in Urothelial Carcinoma
por: Hsu, Fu-Shun, et al.
Publicado: (2017)

Neoadjuvant checkpoint inhibition in renal cell carcinoma associated Stauffer's syndrome
por: Zarrabi, Kevin, et al.
Publicado: (2019)

All for one, but not one for all <Guideline needed; which and when should we use>
por: Notomi, Yuichi
Publicado: (2012)

Next generation sequencing of PD-L1 for predicting response to immune checkpoint inhibitors
por: Conroy, Jeffrey M., et al.
Publicado: (2019)

Management of metastatic endometrial cancer: physicians’ choices beyond the first line after approval of checkpoint inhibitors
por: Arezzo, Francesca, et al.
Publicado: (2023)

Immune-Checkpoint Inhibitors in Advanced Bladder Cancer: Seize the Day
por: Maiorano, Brigida Anna, et al.
Publicado: (2022)

Review of Indications of FDA-Approved Immune Checkpoint Inhibitors per NCCN Guidelines with the Level of Evidence
por: Vaddepally, Raju K., et al.
Publicado: (2020)

Identification of NUDT5 Inhibitors From Approved Drugs
por: Tong, Xin-Yu, et al.
Publicado: (2020)

Impact of Label Restriction on Checkpoint-Inhibitor Use in Bladder Cancer and Changes in Mortality
por: Vader, Daniel T, et al.
Publicado: (2022)

For which lung cancer patients is re-administration of immune checkpoint inhibitors effective?
por: Sasaki, Takanobu, et al.
Publicado: (2021)

Su1188 ABDOMINAL CT SHOULD NOT BE USED TO SCREEN FOR IMMUNE CHECKPOINT INHIBITOR COLITIS
por: Braschi-Amirfarzan, Marta, et al.
Publicado: (2020)

Pre‐approval and post‐approval availability of evidence and clinical benefit of conditionally approved cancer drugs in Europe: A comparison with standard approved cancer drugs
por: Bloem, Lourens T., et al.
Publicado: (2022)

The Rheumatology Drugs for COVID-19 Management: Which and When?
por: Atzeni, Fabiola, et al.
Publicado: (2021)

Role of Perioperative Immune Checkpoint Inhibitors in Muscle Invasive Bladder Cancer
por: Chhaya, Saachi, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_k1a314uv3se675m4dv5mgqsst8